PODD * Stock Overview
Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Insulet Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5,519.04 |
| 52 Week High | US$5,526.00 |
| 52 Week Low | US$2,727.00 |
| Beta | 1.22 |
| 11 Month Change | 21.30% |
| 3 Month Change | n/a |
| 1 Year Change | 79.19% |
| 33 Year Change | -8.87% |
| 5 Year Change | n/a |
| Change since IPO | -8.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| PODD * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 17.4% | 0% | 0% |
| 1Y | 79.2% | 0% | 0% |
Return vs Industry: PODD * exceeded the MX Medical Equipment industry which returned 16.1% over the past year.
Return vs Market: PODD * exceeded the MX Market which returned -3.1% over the past year.
Price Volatility
| PODD * volatility | |
|---|---|
| PODD * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: PODD *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine PODD *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,000 | Jim Hollingshead | www.insulet.com |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally.
Insulet Corporation Fundamentals Summary
| PODD * fundamental statistics | |
|---|---|
| Market cap | Mex$372.01b |
| Earnings (TTM) | Mex$8.58b |
| Revenue (TTM) | Mex$40.45b |
43.4x
P/E Ratio9.2x
P/S RatioIs PODD * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PODD * income statement (TTM) | |
|---|---|
| Revenue | US$1.98b |
| Cost of Revenue | US$608.70m |
| Gross Profit | US$1.38b |
| Other Expenses | US$954.30m |
| Earnings | US$420.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.00 |
| Gross Margin | 69.32% |
| Net Profit Margin | 21.22% |
| Debt/Equity Ratio | 123.4% |
How did PODD * perform over the long term?
See historical performance and comparison